



Performance by design.
Caring by choice.™

CPChem Benefits: CVS Caremark Prescription Drug Plan COVID-19 Provisions

Newly added as of March 24, 2020

Below is a summary of two additional temporary provisions added to your CPChem Prescription Drug Plan on March 24, 2020 in response to the COVID-19 crisis.

Below is a brief description of the two new temporary provisions. Please contact CVS Caremark's customer service line at 1-855-305-3028 with any questions about these temporary provisions.

Extending Prior Authorizations to Maintain Member Access

During this unprecedented time, it may be more challenging for members to see their prescribers — either because of decreased availability of appointments or personal concern over exposure. In order to prevent gaps in therapy, we are extending many clinical prior authorization records — set to expire between March 23 and June 30 — for 90 days. For instance, if a prior authorization is set to expire on May 15, the expiration date will be extended to August 15. Note that there are select drugs to which this **will not apply**.

Preventing Potential Shortages of Key Drugs

While there is no evidence at this time of widespread shortages, it is important to ensure that members with ongoing needs can maintain access to medications, while also enabling patients with COVID-19 to obtain treatment. Some of the medications being identified as possible treatments for COVID-19 are also used by members to treat existing conditions like HIV and lupus. Beginning immediately, we are introducing a utilization management (UM) product bundle, which will institute quantity limits on medications that potentially treat COVID-19 and are used by members for other conditions.

Albuterol Meter Dose Inhalers:

- A quantity limit will be added to albuterol inhalers, limiting them to two per 30 days (200 inhalations per device) at retail or six per 90 days at mail
 - These changes apply only to inhalers and not nebulizer solutions or oral tablets
 - These limits are already commonly used by many of our clients and included in some of our formulary designs

Chloroquine, hydroxychloroquine, Kaletra and azithromycin:

A quantity limit will be added to limit the supply dispensed of these drugs:

- Chloroquine, hydroxychloroquine: 10-day supply, limit of one fill per 60 days
- Kaletra: 14-day supply, limit of one fill per 60 days
- Azithromycin 250 mg tablets, limit of 6 tablets or one blister pack of 6 tablets per five days; limit of one fill per 60 days
- Members are limited to one fill of each product per 60 days

These limits will apply at to claims from all pharmacies. While these medications may be useful in reducing the duration of COVID-19 and we want to ensure appropriate member access for that purpose, it is important to ensure access for members using these medications to treat chronic conditions as well. To minimize disruption for members currently taking these medications, we are implementing the following adjudication logic to identify diagnosis and previous utilization to bypass this limit:

1. If a member has filled a 30-day supply within the previous 180 days, the claim will bypass the quantity limit.
2. If the claim comes through with an appropriate non-COVID-19 diagnosis code, including lupus, rheumatoid arthritis (RA) or HIV, the claim will bypass the quantity limit.

If a member does not have: a claim history for these drugs **OR** a diagnosis code indicating lupus, RA or HIV, the quantity limit will apply. Prescriptions exceeding the quantity limits or with no diagnosis code will require prior authorization to confirm appropriate use.

Note to Participants

This document is presented as a matter of information and as an expression of management policy. It isn't intended to constitute a promise or contractual commitment by the Company. The Company reserves the right to unilaterally change or terminate the program at any time. In the event of any inconsistency with the document and the plan document, plan summary plan document (SPD) or plan prospectus, the plan document, SPD, plan document will control over this document. Employees covered by a collective agreement will also be subject to benefit plan provisions in the applicable collective bargaining agreements.